Angeliki Kotti1, Annica Holmqvist2, Maria Albertsson2, Xiao-Feng Sun3. 1. Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, County Council of Östergötland, University of Linköping, Linköping, Sweden. Electronic address: angkotti@yahoo.gr. 2. Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, County Council of Östergötland, University of Linköping, Linköping, Sweden. 3. Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, County Council of Östergötland, University of Linköping, Linköping, Sweden. Electronic address: xiao-feng.sun@liu.se.
Abstract
PURPOSE: The secreted protein acidic and rich in cysteine-like 1 (SPARCL1) is expressed in various normal tissues and many types of cancers. The function of SPARCL1 and its relationship to a patient's prognosis have been studied, whereas its relationship to radiation therapy (RT) is not known. Our aim was to investigate the expression of SPARCL1 in rectal cancer patients who participated in a clinical trial of preoperative RT. METHODS AND MATERIALS: The study included 136 rectal cancer patients who were randomized to undergo preoperative RT and surgery (n=63) or surgery alone (n=73). The expression levels of SPARCL1 in normal mucosa (n=29), primary tumor (n=136), and lymph node metastasis (n=35) were determined by immunohistochemistry. RESULTS: Tumors with RT had stronger SPARCL1 expression than tumors without RT (P=.003). In the RT group, strong SPARCL1 expression was related to better survival than weak expression in patients with stage III tumors, independent of sex, age, differentiation, and margin status (P=.022; RR = 18.128; 95% confidence interval, 1.512-217.413). No such relationship was found in the non-RT group (P=.224). Further analysis of interactions among SPARCL1 expression, RT, and survival showed statistical significance (P=.024). In patients with metastases who received RT, strong SPARCL1 expression was related to better survival compared to weak expression (P=.041) but not in the non-RT group (P=.569). CONCLUSIONS: SPARCL1 expression increases with RT and is related to better prognosis in rectal cancer patients with RT but not in patients without RT. This result may help us to select the patients best suited for preoperative RT.
RCT Entities:
PURPOSE: The secreted protein acidic and rich in cysteine-like 1 (SPARCL1) is expressed in various normal tissues and many types of cancers. The function of SPARCL1 and its relationship to a patient's prognosis have been studied, whereas its relationship to radiation therapy (RT) is not known. Our aim was to investigate the expression of SPARCL1 in rectal cancerpatients who participated in a clinical trial of preoperative RT. METHODS AND MATERIALS: The study included 136 rectal cancerpatients who were randomized to undergo preoperative RT and surgery (n=63) or surgery alone (n=73). The expression levels of SPARCL1 in normal mucosa (n=29), primary tumor (n=136), and lymph node metastasis (n=35) were determined by immunohistochemistry. RESULTS:Tumors with RT had stronger SPARCL1 expression than tumors without RT (P=.003). In the RT group, strong SPARCL1 expression was related to better survival than weak expression in patients with stage III tumors, independent of sex, age, differentiation, and margin status (P=.022; RR = 18.128; 95% confidence interval, 1.512-217.413). No such relationship was found in the non-RT group (P=.224). Further analysis of interactions among SPARCL1 expression, RT, and survival showed statistical significance (P=.024). In patients with metastases who received RT, strong SPARCL1 expression was related to better survival compared to weak expression (P=.041) but not in the non-RT group (P=.569). CONCLUSIONS:SPARCL1 expression increases with RT and is related to better prognosis in rectal cancerpatients with RT but not in patients without RT. This result may help us to select the patients best suited for preoperative RT.
Authors: Velda J González-Mercado; Jean Lim; Lawrence Berk; Mary Esele; Carmen S Rodríguez; Gerardo Colón-Otero Journal: Curr Probl Cancer Date: 2020-01-27 Impact factor: 3.187
Authors: Elisabeth Naschberger; Andrea Liebl; Vera S Schellerer; Manuela Schütz; Nathalie Britzen-Laurent; Patrick Kölbel; Ute Schaal; Lisa Haep; Daniela Regensburger; Thomas Wittmann; Ludger Klein-Hitpass; Tilman T Rau; Barbara Dietel; Valérie S Méniel; Alan R Clarke; Susanne Merkel; Roland S Croner; Werner Hohenberger; Michael Stürzl Journal: J Clin Invest Date: 2016-10-10 Impact factor: 14.808